Citizens JMP analyst David Turkaly reiterated a Hold rating on Apyx Medical today. The company’s shares closed yesterday at $3.40.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Turkaly covers the Healthcare sector, focusing on stocks such as Apyx Medical, OrthoPediatrics, and Integra Lifesciences. According to TipRanks, Turkaly has an average return of -5.3% and a 38.22% success rate on recommended stocks.
In addition to Citizens JMP, Apyx Medical also received a Hold from BTIG’s Sam Eiber in a report issued yesterday. However, on October 9, Craig-Hallum maintained a Buy rating on Apyx Medical (NASDAQ: APYX).
Based on Apyx Medical’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $11.37 million and a GAAP net loss of $3.78 million. In comparison, last year the company earned a revenue of $12.15 million and had a GAAP net loss of $6.56 million
Read More on APYX:
Disclaimer & DisclosureReport an Issue
- Hold Rating for Apyx Medical Amid Promising Ayon System and Challenging Market Conditions
- Apyx Medical submits FDA 510k to U.S. FDA for label expansion of AYON
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Apyx Medical’s Renuvion APR System: Promising Results in Facelift Surgery Study
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)
/Quantum%20Computing/A%20concept%20image%20with%20a%20brain%20on%20top%20of%20a%20blue%20circuit%20board_%20Image%20by%20Gorodenkoff%20via%20Shutterstock_.jpg)